STOCK TITAN

Vaxart Inc - VXRT STOCK NEWS

Welcome to our dedicated news page for Vaxart (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vaxart's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vaxart's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
clinical trial covid-19
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.03%
Tags
management
Vaxart Inc

Nasdaq:VXRT

VXRT Rankings

VXRT Stock Data

224.28M
157.15M
0.97%
18.15%
8.94%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
South San Francisco

About VXRT

since its founding in 2004, vaxart has pursued a vision of advancing vaccines—to make them as tablets rather than injections. the company’s proprietary oral vaccine delivery platform is suitable to deliver any recombinant vaccine, positioning vaxart to introduce oral forms of multiple vaccines in the rapidly growing global vaccines market.